Abstract
While out-of-town visiting family, a 54-year-old female previously diagnosed with relapsing-remitting multiple sclerosis (RRMS) presented to the clinic as a new patient to be evaluated for a recent exacerbation, manifesting with abrupt onset of constant, mild vertigo, and increasingly frequent falls, with progressive deterioration over the last 6 weeks. She also had some mild nausea, but denied any emesis or weight loss. There were no cognitive, personality, or behavioral changes reported.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Cordioli C, De Rossi N, Rasia S, Lodoli G, Capra R. Early detection and favourable outcome of natalizumab-related progressive multifocal leukoencephalopathy (PML) in two multiple sclerosis patients. Neurol Sci. 2015;36:489-491.
Wattjes MP, Barkhof F. Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI. Curr Opin Neurol. 2014;27:260-270.
Babi M-A, Pendlebury W, Braff S, Waheed W. JC Virus PCR detection Is not infallible: a fulminant case of progressive multifocal leukoencephalopathy with false-negative cerebrospinal fluid studies despite progressive clinical course and radiological findings. Case Rep Neurol Med. 2015;2015:4.
Rudick RA, Sandrock A. Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev Neurother. 2004;4:571-580.
Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899-910.
Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354:911-923.
Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366:1870-1880.
Engsig FN, Hansen A-BE, Omland LH, et al. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J Infect Dis. 2009;199:77-83.
Sahraian MA, Radue EW, Eshaghi A, Besliu S, Minagar A. Progressive multifocal leukoencephalopathy: a review of the neuroimaging features and differential diagnosis. Eur J Neurol. 2012;19:1060-1069.
Khatri BO, Man S, Giovannoni G, et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology. 2009;72:402-409.
Rushing EJ, Liappis A, Smirniotopoulos JD, et al. Immune reconstitution inflammatory syndrome of the brain: case illustrations of a challenging entity. J Neuropathol Exp Neurol. 2008;67:819-827.
Giacomini PS, Rosenberg A, Metz I, Araujo D, Arbour N, Bar-Or A; MIMSTAPI group. Maraviroc and JCvirus-associated immune reconstitution inflammatory syndrome. N Engl J Med. 2014; 370:486-488.
Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A. Natalizumabassociated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010;9:438-446.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Eckstein, C. (2017). Progressive multifocal leukoencephalopathy. In: Giacomini, P. (eds) Case Studies in Multiple Sclerosis. Adis, Cham. https://doi.org/10.1007/978-3-319-31190-6_6
Download citation
DOI: https://doi.org/10.1007/978-3-319-31190-6_6
Published:
Publisher Name: Adis, Cham
Print ISBN: 978-3-319-31188-3
Online ISBN: 978-3-319-31190-6
eBook Packages: MedicineMedicine (R0)